Etoricoxib in the management of inflammation and pain in patients with cardiovascular disorders Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
etoricoxib, NSAIDs, non-steroidal anti-inflammatory drugs, safety, efficacy, pain therapy
Main Article Content
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs), despite the dynamic progress in targeted pharmacotherapy, have consistently remained the foundation for symptomatic management of pain in numerous disorders. This short review aims at comprehensive elucidating the key differences among selected NSAIDs, with a specific focus on etoricoxib, which has recently gained popularity due to favorable research results regarding its efficacy and, most importantly, its relative safety profile. Special emphasis has been placed on cardiovascular safety, including interactions with concurrently administered acetylsalicylic acid in the context of maintaining its cardioprotective effectiveness while using simultaneously with NSAIDs. The impact of NSAIDs on the risk of gastrointestinal bleedings is also discussed, and an algorithm for selecting an appropriate analgesic and anti-inflammatory drug is proposed based on the gastrointestinal risk and the coexistence of cardiovascular disorders.
Article Details
How to Cite
Gajecki, D., & Doroszko, A. (2024). Etoricoxib in the management of inflammation and pain in patients with cardiovascular disorders. Medycyna Faktow (J EBM), 17(1(62), 58-64. https://doi.org/10.24292/01.MF.0124.09
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Keshwani S, Grande I, Maguire M et al. Trends in Use of Prescription Nonsteroidal Anti-inflammatory Medications Before vs After Implementation of a Florida Law Restricting Opioid Prescribing for Acute Pain. JAMA Netw Open. 2021; 4(6): e2113383. http://doi.org/10.1001/jamanetworkopen. 2021.13383.
2. Global Non-steroidal Anti-inflammatory Drugs Market by Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), Drugs (Over-the-counter Drugs, Prescription), Route of Administration, Distribution Channel – Forecast 2023-2030.
3. Badimon L, Vilahur G, Rocca B et al. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021; 117(9): 2001-15. http://doi.org/10.1093/cvr/cvab003.
4. Chan FKL, Hung LCT, Suen BY et al. Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis. N Engl J Med. 2002; 347(26): 2104-10. http://doi.org/10.1056/NEJMoa021907.
5. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. Am J Gastroenterol. 2006; 101(4): 701-10. http://doi.org/10.1111/j.1572-0241.2006.00499.x.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. JAMA. 2000; 284(10): 1247. http://doi.org/10.1001/jama.284.10.1247.
7. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364(9435): 675-84. http://doi.org/10.1016/S0140-6736(04)16894-3.
8. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. N Engl J Med. 2001; 345(25): 1809-17. http://doi.org/10.1056/NEJMoa003199.
9. Reed GW, Abdallah MS, Shao M et al. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. J Am Coll Cardiol. 2018; 71(16): 1741-51. http://doi.org/10.1016/j.jacc.2018.02.036.
10. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69(3): 365-71. http://doi.org/10.1007/s00228-012-1370-y.
11. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology. 2009; 48(4): 425-32. http://doi.org/10.1093/rheumatology/kep005.
12. Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014; 2019(5). http://doi.org/10.1002/14651858.CD004309.pub4.
13. Moore RA, Derry S, Aldington D et al. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. Published online September 28, 2015. http://doi.org/10.1002/14651858.CD008659.pub3.
14. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease 2020 (11th ed).
15. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 1809-17.
16. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69(3): 365-71.
2. Global Non-steroidal Anti-inflammatory Drugs Market by Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), Drugs (Over-the-counter Drugs, Prescription), Route of Administration, Distribution Channel – Forecast 2023-2030.
3. Badimon L, Vilahur G, Rocca B et al. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021; 117(9): 2001-15. http://doi.org/10.1093/cvr/cvab003.
4. Chan FKL, Hung LCT, Suen BY et al. Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis. N Engl J Med. 2002; 347(26): 2104-10. http://doi.org/10.1056/NEJMoa021907.
5. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. Am J Gastroenterol. 2006; 101(4): 701-10. http://doi.org/10.1111/j.1572-0241.2006.00499.x.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. JAMA. 2000; 284(10): 1247. http://doi.org/10.1001/jama.284.10.1247.
7. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364(9435): 675-84. http://doi.org/10.1016/S0140-6736(04)16894-3.
8. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. N Engl J Med. 2001; 345(25): 1809-17. http://doi.org/10.1056/NEJMoa003199.
9. Reed GW, Abdallah MS, Shao M et al. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. J Am Coll Cardiol. 2018; 71(16): 1741-51. http://doi.org/10.1016/j.jacc.2018.02.036.
10. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69(3): 365-71. http://doi.org/10.1007/s00228-012-1370-y.
11. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology. 2009; 48(4): 425-32. http://doi.org/10.1093/rheumatology/kep005.
12. Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014; 2019(5). http://doi.org/10.1002/14651858.CD004309.pub4.
13. Moore RA, Derry S, Aldington D et al. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. Published online September 28, 2015. http://doi.org/10.1002/14651858.CD008659.pub3.
14. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease 2020 (11th ed).
15. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 1809-17.
16. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69(3): 365-71.